FDA approves 2-dose biologic Exdensur for severe eosinophilic asthma in patients 12 and older, reducing exacerbations and hospital visits.

For a carbon-neutral bioeconomy, processes are needed that can efficiently capture CO2 and convert it into valuable products.

Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the ...

Fortress Biotech ( ($FBIO) ) has provided an announcement. On December 15, 2025, Fortress Biotech announced that the U.S. FDA accepted the ...

Fly this December and receive exclusive wildlife-themed amenity kits, highlighting endangered species with eco-friendly ...

Coming up in the back half of December, the FDA will issue a verdict on Vanda Pharmaceuticals’ gastroparesis drug tradipitant ...

Indian students applying for F-1 visas to study in the US must present specific mandatory documents, including passports, ...

Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, ...

Detailed price information for Assembly Biosciences (ASMB-Q) from The Globe and Mail including charting and trades.

The company has also received orphan drug, rare pediatric disease, and fast-track designations for LTS-101 as a potential treatment for the fatal neurodegenerative disease.

Research on the long-term impacts of short-form video consumption is still lacking, but recent studies show concerning ...

Researchers say in future it may be possible to grow personalized organoids from patient’s own tissue, to test potential treatments in advance.